Frequency And 13x Per Day The one to three times per day frequency in community protocols follows directly from the short half-life of both blend components: because a no-DAC GHRH signal and an Ipamorelin pulse each last on the order of a couple of hours, a once-daily model produces one reinforced pulse, while a multiple-times-daily model attempts to reinforce several natural pulses across the day
Key published studies include: Teichman et al., 2006 (JCEM): Dose-dependent GH and IGF-1 elevation with CJC-1295 DAC in healthy adults Raun et al., 1998 (Eur J Endocrinol): Ipamorelin demonstrated selective GH release without cortisol/prolactin elevation Johansen et al., 1999: Phase I/II Ipamorelin trial showed dose-response relationship with no significant adverse effects Bowers et al., 2004: Foundational research on GHRH/GHRP synergistic GH release mechanisms Neither CJC-1295 nor Ipamorelin has completed Phase 3 clinical trials
Abnormal IGF-1 levels can lead to various health problems: Excessively high levels of IGF-1 at any stage in life can cause a rare condition known as acromegaly (gigantism)
CJC-1295 should not be used without medical supervision because dosing, cycle length, side effects, lab markers, and health history all matter
Highlight pricing gaps, suspension issues, feed inconsistencies and trading anomalies before they materially affect turnover, margin or customer experience during high-volume windows
